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Abstract
A series of di- and triorganotin 3,6-dioxaheptanoates and 3,6,9-trioxadecanoates were synthesized and
characterized by IH, 13C and l7Sn NMR, electrospray mass and l9mSn M6ssbauer spectroscopy, as well as
elemental analysis. Their in vitro antitumour activity against seven tumoural cell lines of human origin, two
breast cancers (MCF-7, EVSA-T), a colon carcinoma (WiDr), an ovarian cancer (IGROV), a melanoma (M19
MEL), a renal cancer (A 498) and a non small cell lung cancer (H 226), is reported. They are characterized by
similar inhibition doses IDs0 as the analogous di- and triorganotin derivatives of 4-carboxybenzo-15-crown-5
and -18-crown-6 and in some cases by much lower IDs0 values than clinically used reference compounds such
as doxorubicine and methotrexate.
Introduction
Many di-n-butyl, tri-n-butyl and triphenyltin carboxylates display interesting antitumour activities in vitro
against tumour cell lines of human origin [1,2]. As early as 1985, Atassi suggested that the usually low water
solubility of organotin compounds might be the major drawback to the improvement of their antitumour
properties [3]. One possibility to increase water solubility is to replace methylene groups in a polymethylenic
chain by oxygen atoms [4]. Accordingly, some new organotin derivatives of 3,6-dioxaheptanoic and 3,6,9-
trioxadecanoic acid were synthesized. This report presents their synthesis, characterization and in vitro
antitumour activity.
Results and discussion
Synthesis
For the triorganotin polyoxaalkanoates, the condensation is carried out in benzene using triphenyltin hydroxide
respectively tri-n-butyltin acetate and either 3,6-dioxaheptanoic or 3,6,9-trioxadecanoic acid (equations and
2) [2-5].
(C6H5)3SnOH + RCOOH (C6H5)3SnOCOR + H20 (1)
Bu3SnOCOCH3 + RCOOH Bu3SnOCOR + CH3COOH (2)
For the diorganotin polyoxaalkanoates, di-n-butyltin oxide first reacts with n-propanol to form
tetrabutyldipropoxydistannoxane (equation 3) [6].
2 BuzSnO + 2 PrOH (PrOSnBu2)20 + H20 (3)
Subsequently, the polyoxaalkanoic acid is added at room temperature to the tetrabutyldipropoxydistannoxane
in the desired molar ratio. A molar ratio 1/1 generates the corresponding bis[di-n-
butyl(polyoxaalkanoato)tin]oxide (equation 4); a molar ratio 2/1 leads to the di-n-butyitin
bis(polyoxaalkanoate) (equation 5).
2 (PrOSnBu2)20 + 4 RCOOH
(PrOSnBu2)20 + 4 RCOOH
[Bu2(RCOO)Sn]20 2 + 4 PrOH (4)
2 Bu2Sn(OCOR)2 + 2 PrOH + H20 (5)
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Sephadex LH-20 chromatography proved to be very efficient to separate the bis[di-n-
butyl(polyoxaalkanoato)tin]oxides and tributyl- or triphenyltin polyoxaalkanoate from the starting material.
The di-n-butyltin bis(polyoxaalkanoates) were hydrolyzed on Sephadex LH-20 into bis[di-n-
butyl(polyoxaalkanoato)tin]oxides (equation 6). Hydrolysis was also observed in the presence of wet ethanol,
diorganotin dicarboxylates often undergoing partial hydrolysis to form the dimeric distannoxanes [7].
4 Bu2Sn(OCOR)2 + 2 H20
The compounds synthesized are depicted in figure 1.
[Bu2(RCOO)Sn]20 }2 + 4 RCOOH (6)
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figure 1
1 2 3 4
CH(o) 7.7-7.8 m [65]
CH(m)(p) 7.4-7.5 m
CH2(2) 4.25 s 4.09 s
CH2(4) 3.7-3.8 m 3.6-3.7 m
CH2(5) 3.5-3.6 m 3.5-3.6 m
CH3(7) 3.35 s 3.36 s
HOH -2.2 bs
CH2(]) 1.5-1.6 m
CH2() 1.2-1.4 m
CHz(y) 1.2-1.4 m
4.16 s 3.95 s
3.6-3.8 m 3.6-3.7 m
3.5-3.6 m 3.5-3.6 m
3.36 s 3.34 s
~2.0 s
1.6-1.7 m 1.5-1.7 m
1.6-1.7 m [100] 1.3-1.5 m
1.34 tq (7, 7) 1.30 tq (7, 7)
CH3(6) 0.88 (7) 0.87 (7) 0.8-0.9 m
Table 1’ H NMR data in CDCI of compounds 1 to 4’ chemical shifts in ppm with respect to TMS" coupling
constants in Hz, nj(1H -IH) in parentheses, nj(1H-117/119Sn) between square brackets. Abbreviations: singlet; m
complex pattern; b broad" triplet; tq triplet of quartets.
Characterization
NMR spectroscopy
All compounds were characterized by IH, 13C, and l7Sn NMR in CDC13. The IH NMR data are listed in
tables and 2. The proton chemical shifts of the carboxylate moiety were assigned by IH-,13C HMBC and
HMQC experiments. The methylenic H(4), H(5) and H(7) proton resonances of compounds 1-5 appear as non
overlapping patterns, those of compounds 6-8 do not. 3j(IH-! 17/119Sn) coupling constants could be determined
for compounds 1 and 5, and 2j(IH-117/119Sn) coupling constants, for compounds 3 and 7.
The 13C NMR data are given in tables 3 and 4. Signal assignment was carried out by IH-13C HMQC and
HMBC experiments. 13C resonances of tri-n-butyltin and triphenyltin moieties were assigned straightforwardly
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from the nj(13c-ll7/ll9Sn) coupling constants [8,9]. Compounds 4 and 8 show pairs of 13C resonances for
each carbon type of the di-n-butyltin moieties. These are broad, precluding the observation of
nj(13C llT/ll9Sn) satellites.
5 6 7 8
CH(o) 7.7-7.8 m [60]
CH(m)(p) 7.4-7.5 m
CH2(2) 4.22 s 4.09 s 4.15 s
CH2(4) 3.7-3.8 m 3.6-3.8 m 3.6-3.8 m
CH2(5) 3.6-3.7 m 3.6-3.8 m 3.6-3.8 m
CH2(7) 3.5-3.6 m 3.6-3.8 m 3.6-3.8 m
CH2(8) 3.4-3.5 m 3.5-3.6 m 3.5-3.6 m
CH3(10) 3.34 s 3.36 s 3.35 s
HOH --.1.9 b
CH2() 1.5-1.7 m 0.6-0.8 m
CHz(t) 1.2-1.4 m 0.6-0.8 m
CH2(]0 1.2-1.4 m 1.35 tq
CH3(5 0.89 (7) 0.88
Table 2: 1H NMR data in CDC13 of compounds 5 to 8, see legend table 1.
[102]
(7, 7)
(7)
3.96 s
3.6-3.7 m
3.6-3.7 m
3.6-3.7 m
3.5-3.6 m
3.34 s
--1.9 b
1.57 tt
1.4-1.5 m
1.27 tq
0.8-0.9 m
(7, 7)
(7, 7)
The 117Sn NMR data are reported in table 5. Compounds 1, 2, 3, 5, 6 and 7 exhibit one single 117Sn
resonance. Compounds 4 and 8 exhibit two 117Sn resonances of equal intensities, resulting from the dimeric
structure characterized by endocyclic and exocyclic tin atoms (see figure 1).
1 2 3 4
C(1) 176.5 175.2 178.3
CH(i) 137.7
CH(o) 136.8 [49]
CH(p) 130.2 [13]
CH(m) 128.9 [62/65]
CH2(5) 72.0 71.9 71.8
CH2(4) 70.6 70.4 70.7
CH2(2) 69.0 69.0 68.6
CH3(7) 59.0 59.0 59.0
CH2(13) 27.8 [20] 26.5 [34]
CH2(Y) 27.1 [64/67] 26.3 [98/102]
CH2(c) 16.6 [338/355] 25.7 [538/567]
CH3(i) 13.7 13.4 [5]
174.9
71.8
70.2
69.8
58.9
27.5
27.2
26.8
26.7
29.0
26.3
13.57
13.55
Table 3: 13C NMR data in CDCI of compounds 1 to 4; chemical shifts in ppm with respect to TMS;
nj(13C 117/119Sn) coupling constants in Hz between square brackets.
M6ssbauer spectroscopy
The Mtssbauer parameters are shown in Table 6. The quadrupole splittings QS are found in the range 3.49-
3.90 mm/s. Since M6ssbauer spectroscopy is less sensitive to small variations of the tin environment than tin
NMR spectroscopy, the two different tin atoms in 4 and 8 could not be discriminated. The Mtssbauer
parameters are in agreement with a polymeric structure for the triorganotin polyoxaalkanoates, in which tin is
five-coordinate with a trans-02 configuration [2]. For the diorganotin polyoxaalkanoates, the QS values
conform the structures of figure 1.
Electrospray mass spectroscopy
The monoisotopic mass spectra (IH, 12C, 160, 12Sn) in the cationic mode of water/acetonitrile solutions are
reported in Table 7. All compounds are easily complexed by normal or hydrolyzed fragments, or solvent
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molecules. The hydrolyzed species give an indication about stability inside the spectrometer [10]. They are
observed for all compounds, but only fragments providing straightforward characterization ofM are listed.
5 6 7 8
C(1) 176.4 175.1 175.8 175.1
CH(i) 137.8
CH(o) 136.9 [47/50]
CH(p) 130.2 [13]
CH(m) 128.9 [62/66]
CH2(8) 72.0 72.0 71.8 72.0
CH2(4)(5) and (7) 70.7 70.6 71.1 70.60
70.7 70.5 70.6 70.55
70.5 70.5 70.4 70.4
CH2(2) 69.0 69.0 68.7 69.9
CH3(10) 59.0 58.9 59.0 59.0
CH2(I3) 27.8 [20] 26.6 [38] 27.6
27.3
CH2(Y) 27.0 [63/66] 26.3 [99] 26.9
26.7
CH2(c) 16.6 [339/355] 25.6 [540/567] 29.1
25.8
CH3(5) 13.6 13.5 13.6
Table 4: 13C NMR data in CDC13 of compounds 5 to 8, see legend table 3.
1 2 3 4 5 6 7 8
-100.0 120.7 -124.7 -204.8 -103.2 120.7 -124.1 -204.9
-215.8 -217.6
[n.o.] [1191
Table 5: llTSn NMR data in CDC13 of compounds 1 to 8; chemical shifts in ppm with respect to (CH3)4Sn; coupling
constants 2j(ll7Sn-llT/ll9Sn) in Hz in square brackets; n.o.: not observed.
QS IS F F2
1 3.60 1.24 0.85 0.79
2 3.81 1.47 1.15 1.14
3 3.90 1.44 1.28 1.02
4 3.42 1.34 1.22 1.18
5 3.44 1.29 0.91 0.87
6 3.84 1.47 1.07 1.02
7 3.77 1.42 1.36 1.18
8 3.49 1.32 0.90 0.90
Table 6: l9mSn MOssbauer parameters: QS (mm/s) quadrupole splitting, IS (mm/s)
isomer shift relative to Callgsno3, F and F: (mm/s) line width.
Elemental analysis
C and H elemental analysis was achieved for all compounds (see table 8).
Compounds 2 and 6 contain water in a (2/1) tributyltin carboxylate/water ratio. The dimeric compounds 4 and
8 are found to contain two molecules of water per dimeric distannoxane unit. The presence of water is
confirmed by the proton NMR spectra (see Tables and 2).
In vitro antitumour screening
All compounds were screened against seven tumoural cell lines of human origin.
The IDs0 values are reported in Table 9 and compared to those of some drugs with clinical applications and of
organotin carboxylates containing crown ether moieties: di-n-butyl, tri-n-butyl and triphenyltin derivatives of
4-carboxybenzo-18-crown-6 and -15-crown-5 [11] of which the structures are depicted in figure 2. The two
series (1 to 4 and 5 to 8) show pairwise comparable activities.
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fragment 1 5
M + H+ 485; 2% 529; 6%
M + Ph3Sn+ 835; 100% 879; 100%
M + H+ 425; 2%
M + Bu3Sn+ 715; 100% 759; 100%
[RCOOSnBu2]+ 367; 9% 411; 13%
M + H+ 501; 5% 589; 23%
[RCOOBu2SnOSnBu:z]+ 617; 100%
[RCOOBu2SnOSnBu2OSnBu2]+ 867; 62%
RCOOBu2SnOSnBuzOCOR + [BuSnOH]+ 1001; 40%
Table 7: Characteristic electrospray fragment-ions for compounds 1 to 8.
structure C H
1 C23H24SnO4 57.2 [57.39] 5.0 [4.67]
2 CI7H36SnO4.1/2H20 47.3 [47.35] 8.6 [8.57]
3 CIsH36SnO8 43.3 [43.40] 7.3 [7.48]
4 CszHogSn40s’2H20 40.8 [40.72] 7.4 [7.21]
5 C25Hz8SnO5 57.0 [57.06] 5.4 [5.36]
6 CI9H4oSnOs.1/2H20 47.9 [47.70] 8.7 [8.78]
"7 C22H44SnOI0 45.0 [44.80] 7.6 [7.76]
8 C60HI24Sn4022.2H:zO 42.2 [42.15] 7.6 [7.44]
Table 8: Elemental analysis of compounds 1 to 8 (found [calculated]).
661; 100%
911; 70%
1089; 33%
MCF-7 EVSA-T WiDr IGROV M19MEL A 498 H 226
1 13 12 34 37 31 32 33
2 32 40 82 84 90 153 61
3 60 62 379 128 115 134 161
4 <3 <3 6 <3 <3 <3 5
5 9 9 19 33 24 21 25
6 36 25 40 89 78 93 56
7 86 66 495 178 167 145 280
8 <3 <3 3 <3 <3 <3 <3
9 15 12 13 30 16 43 37
1 0 35 6 11 30 70 97 100
1 1 155 128 781 260 219 282 281
1 2 36 46 239 82 68 126 73
13 <3 <3 <3 <3 <3 <3 <3
1 4 <3 <3 <3 <3 <3 <3 <3
1 5 273 237 332 321 286 49 854
cisplatin 699 422 967 169 558 2253 3269
doxorubicine 10 8 11 60 16 90 199
etoposide 2594 317 150 580 505 1314 3934
5-fluorouracil 750 475 225 297 442 143 340
methotrexate 18 5 <3 7 23 37 2287
Table 9: In vitro inhibition doses IDs0 (in ng/ml) against seven cancer cell lines of human origin,
MCF-7 and EVSA-T, two breast cancers; WiDr, a colon carcinoma; IGROV, an ovarian cancer; M19
MEL, a melanoma, A 498 a renal cancer and H 226, a non small cell lung cancer. The structures of
compounds 9 to 15 are depicted in figure 2.
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Compounds 4 and 8 exhibit exceptionally low inhibition doses and are comparable to those of
compounds 13 and 14. Activities of 3 and 7 are very different from those of 4 and 8. The
former can easily be hydrolyzed into the latter as was already announced previously. Hydrolysis
of 4 and 8 has no determinant effect on in vitro antitumoural activity.
R""’xx OR
R’
R’= C6H5, R R 9
R’ C6H5, R R2 13
R’= Bu, R R1 10
R’ Bu, R R2 14
Bu
Bu
R=Rlll
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R
O
Bu’"mtt/Sn
l
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R
R
Sn
R R1 12
0
0 00
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figure 2
Experimental part
Synthesis
Triorganotin carboxylates
Compounds 1 and 5 are typically prepared by mixing equimolar quantities of triphenyltin hydroxide and the
desired polyoxacarboxylic acid in 250 ml benzene in a 500 ml flask equipped with a Dean-Stark funnel. The
mixture is refluxed for 8 to 12 hours. The binary azeotrope benzene/water is distilled off up to 50% to the
initial solvent volume. The remaining solution is evaporated under vacuum.
The synthesis with tri-n-butyltin acetate yielding 2 and 6 is analog.
m.p. yield
1 100-102C 95%
2 liquid 95%
3 liquid 98%
4 liquid 80%
5 109-111C 92%
6 liquid 92%
7 liquid 95%
8 liquid 80%
purification method
recystallization from hexane/chloroform
Sephadex LH-20; elution with methylene chloride
no purification
Sephadex LH-20; elution with methylene chloride
recrystallization from diethylether/methylene chloride
Sephadex LH-20; elution with methylene chloride
no purification
Sephadex LH-20; elution with methylene chloride
Table 10: Synthesis data for compounds 1 to 8.
Diorganotin carboxylates
Di-n-butyltin oxide is allowed to react with 1-propanol (typically g of di-butyltin oxide and 4 ml of 1-
propanol) in benzene (250 ml) in a 500 ml three-necked flask. The reaction mixture is refluxed for 3 hours
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under elimination of the ternary azeotrope benzene/water/1-propanol (Dean-Stark). After cooling to room
temperature, the appropriate amount of polyoxaalkanecarboxylic acid (1/1 molar ratio polyoxaalkanecarboxylic
acid / di-n-butyltin oxide for 3 and 7; 2/lmolar ratio for 4 and 8) is added slowly and the mixture is stirred
overnight. The solvent is then evaporated and the product treated as indicated in Table 10 in which all
experimental synthesis details are summarized.
NMR measurements
All 2D NMR spectra and some of the 1D spectra were recorded on a Bruker AMX500 spectrometer interfaced
with a X32 computer and operating at 500.13 and 125.77 MHz for the IH and 13C nuclei, respectively. All
NMR spectra except H and 13C of compound 4 were acquired on a Bruker AC250 instrument equipped with a
Quattro probe tuned to 250.13, 62.93 and 89.15 MHz for H, 3C and llTSn nuclei respectively. IH and 3C
chemical shifts were referenced to the standard Me4Si scale from respectively residual H and 3C-2H solvent
resonances of chloroform (CHC13, 7.23 and CDC13, 77.0 ppm for IH and 3C nuclei, respectively). The lTSn
resonance frequencies were set from the absolute reference -Z(lTSn) 35.632295 MHz[2,3]. 2D gradient
enhanced IH-3C HMQC[14] and HMBC[5] correlation spectra were acquired using the pulse sequences of the
Bruker program library, adapted to include gradient pulses,[619] as described recently[2].
MOssbauer spectroscopy
The M6ssbauer spectra were recorded as described elsewhere[2].
Mass spectrometry
The electrospray mass spectra were recorded in the cationic mode on a Micromass Quattro II instrument
coupled with a Masslynx system (ionisation in an electric field of 3,5 kV; source temperature: 80C; source
pressure: atm; analyzer pressure: 10-5 mbar)[22,23]. Cone voltages were 30 V for compounds 1 to 3 and 5 to
7, and 70 V for compounds 4 and 8.
Antitumour screening
The protocol followed for the antitumour screenings has already been reported[24,25].
Acknowledgements
We thank Mrs. I. Verbruggen and Mr. L. Ghys for recording NMR spectra, Dr. G. Laus and Mr. M. Desmet
for the mass spectra and Prof. Dr. B. Mahieu for the M6ssbauer spectra. We are grateful to Mr. H. J. Kolker,
Dr. J. Verweij, Prof. Dr. G. Stoter, Dr. J. H. M. Schellens, Laboratory of Experimental Chemotherapy and
Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute, NL 3008 AE, Rotterdam, The
Netherlands, for performing the in vitro screenings. This research was supported by the "Ministre de
l’Education Nationale du Luxembourg" (grants nr BFR93/051, BPU96/130 and BPU97/138, M. K.), the
"Action Lions Vaincre le cancer du Luxembourg" (M. K), the Belgian "Nationaal Fonds voor
Wetenschappelijk Onderzoek" (N.F.W.O. grant nr G.0054.96, M. G.), and the Fund for Scientific Research
Flanders (Belgium, grant nr G.0192.98, R. W., M. B.).
References
M. Gielen, Tin-based antitumour drugs, Coord. Chem. Rev. 151 (1996), 41-51.
[2] R. Willem, A. Bouhdid, M. Biesemans, J. C. Martins, D. de Vos, E. R. T. Tiekink, M. Gielen, J.
Organomet. Chem. 541 (1996), 203; R. Willem, A. Bouhdid, B. Mahieu, L. Ghys, M. Biesemans, E. R. T.
Tiekink, D. de Vos, M. Gielen, J. Organomet. Chem. 531 (1997), 151.
[3] G. Atassi, Rev. Si, Ge, Sn, Pb cpds. 8 (1985), 219.
[4] D. J. Cram, G. S. Hammond, in "Organic Chemistry", McGraw-Hill Book Company, NY, (1959), pp.
158-162.
[5] M. Gielen, A. E1 Khloufi, M. Biesemans, R. Willem, Appl. Organomet. Chem. 7 (1993), 119.
[6] A. G. Davies, D. C. Kleinschmidt, P. R. Palan, S. C. Vasishtha, J. Chem. Soc. (C) (1971), 3972.
[7] D. L. Alleston, A. G. Davies, M. Hancock, R. F. M. White, J. Chem. Soc. (1963), 5469.
[8] B. Wrackmeyer, Annu. Rep. NMR Spectrosc. 16 (1985), 73.
[9] B. Wrackmeyer, in "Advanced Applications of NMR to Organometallic Chemistry", Ed.: M. Gielen, R.
Willem, B. Wrackmeyer, J. Wiley, Chichester (1996), pp. 87-122.
[10] W. Henderson, M. J. M. Taylor, Polyhedron 15 (1996), 1957.
11 M. Kemmer, M. Gielen, M. Biesemans, D. de Vos, R. Willem, unpublished results.
[12] J. Mason, Multinuclear NMR, Plenum Press, NY, (1987), pp. 625-629.
195Vol. 5, No. 4, 1998 Synthesis, Characterization and In Vitro Antitumour Activity ofDI-n-Butyl
[13] A. G. Davies, P. G. Harrison, J. D. Kennedy, R. J. Puddephatt, T. N. Mitchell, W. J. McFarlane, J.
Chem. Soc. (A) (1969), 1136.
[14] A. Bax, R. H. Griffey, B. H. Hawkins, J. Magn. Reson. 55 (1983), 301.
[15] A. Bax, M. F. Summers, J. Magn. Reson. 67 (1986), 565.
[16] J. Keeler, R. T. Clowes, A. L. Davis, E. D. Laue, Meth. Enzymol. 239 (1994), 145.
[17] J.-M. Tyburn, I. M. Bereron, D. M. Doddrell, J. Magn. Reson. 97 (1992), 305.
[18] J. Ruiz-Cabello, G. W. Vuister, C. T. W. Moonen, P. Van Gelderen, J. S. Cohen, P. C. M. Van Zijl, J.
Magn. Reson. 100 (1992), 282.
[19] G. W. Vuister, R. Boelens, R. Kaptein, R. E. Hurd, B. K. John, P. C. M. Van Zijl, J. Am. Chem. Soc.
113 (1991), 9688.
[20] R. Willem, A. Bouhdid, F. Kayser, A. Delmotte, M. Gielen, J. C. Martins, M. Biesemans, B. Mahieu,
E. R. T. Tiekink, Organometallics 15 (1996), 1920.
[21] M. Bout.lain, R. Willem, M. Biesemans, B. Mahieu, J. Meunier-Piret, M. Gielen; Main Group Met.
Chem. 14 (1991), 41.
[22] G. Lawson, R. H. Dahm, N. Ostah, E. D. Woodland, Appl. Organomet. Chem. 10 (1996), 125.
[23] G. Lawson, N. Ostah, Appl. Organomet. Chem. 8 (1994), 525.
[24] Cancer: principles and practice of oncology, Eds.: V. T. DeVita Jr., S. Hellman, S. A. Rosenberg, 5th
Ed. (1997), Lippincott-Raven Publ., Philadelphia.
[25] Y. P. Kepers, G. J. Peters, J. Van Ark-Otte, B. Winograd, H. M. Pinedo, Eur. J. Cancer 27 (1991), 897.
Received" June 23, 1998 Accepted" July 14, 1998
196